Key result
Metalloproteinases induce the remodeling process of the cardiac tissue in both beneficial and detrimental ways, which may be limited by tissue inhibitors of metalloproteinase and pharmacological agents.
Why the study?
The review aimed to analyze the impact of metalloproteinases on cardiac remodeling and the factors affecting their activity.
This review highlights the complex, dual role of metalloproteinases in cardiac remodeling and the potential for pharmacological modulation.
Answers are grounded in this paper and cite their sources.
Metalloproteinase modulation in cardiac remodeling remains investigational; leaves open net clinical benefit and optimal targets.
During the last years metalloproteinases as a family of proteases have been implicated in various human diseases and catalytic mechanisms of pathological disorders. Metalloproteinases can be divided into two subgroups, matrix metalloproteinases (MMPs) and adamalysins (ADAMs). The MMPs consist of 6 basic subgroups which are inhibited by the tissue inhibitors of metalloproteinase (TIMP), while ADAMs consists of approximately 40 members. It is confirmed that metalloproteinases are an important factor for the cardiac remodeling process, interfering with the alteration of the cardiac structure induced by cardiac injury or increased haemodynamic load. The aim of this review is the analysis of the impact of metalloproteinases on cardiac remodeling and the factors affecting metalloproteinase activity. Metalloproteinases induce the remodeling process of the cardiac tissue in both beneficial and detrimental ways. TIMPs and various administered pharmacological agents may limit the effectiveness of metalloproteinases, therefore interfering in cardiac remodeling.
No takes yet. Share an insight, caveat, or question.
Anestakis et al. (2019) conducted a review in Cardiac remodeling. Metalloproteinases was evaluated. Metalloproteinases induce the remodeling process of the cardiac tissue in both beneficial and detrimental ways, which may be limited by tissue inhibitors of metalloproteinase and pharmacological agents.
Synapse has enriched 10 related papers. Consider them for comparative context: